

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



Flasche, S (2017) The scope for pneumococcal vaccines that do not prevent transmission. *Vaccine*, 35 (45). pp. 6043-6046. ISSN 0264-410X DOI: <https://doi.org/10.1016/j.vaccine.2017.09.073>

Downloaded from: <http://researchonline.lshtm.ac.uk/4503960/>

DOI: [10.1016/j.vaccine.2017.09.073](https://doi.org/10.1016/j.vaccine.2017.09.073)

#### Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

## 1 Background

2 Pneumococcal conjugate vaccines (PCVs) have now been included into most national childhood  
3 immunisation programmes worldwide [1], primarily to reduce morbidity and mortality during  
4 childhood [2]. A striking feature of national PCV infant immunisation programmes, however, has  
5 been the added benefit of herd protection [3,4] which has led to near elimination of vaccine  
6 serotype (VT) disease within a few years after PCV introduction [5]. This indirect benefit is  
7 particularly relevant in high income settings where a substantial proportion of vaccine preventable  
8 pneumococcal disease occurs among older individuals.

9 PCVs, however, only target a small subset of the more than 90 pneumococcal serotypes. Hence, PCV  
10 use created an ecological niche that was instantaneously filled by untargeted serotypes (serotype  
11 replacement) [6], and mitigated some of their impact [5]. To circumvent the problem of  
12 replacement disease, several vaccine candidates are being developed. Some aim to expand the  
13 serotype coverage of current PCVs to serotypes that are the primary cause of replacement disease.  
14 Other approaches, including whole cell vaccines and common protein vaccines, aim at capsule-  
15 independent protection against all pneumococci [7], either to be used in combination with PCVs or  
16 as an alternative. A benefit of candidates without a PCV component is that those avoid the costly  
17 conjugation process. Hence, they can improve affordability of pneumococcal vaccines which is of  
18 much concern to many low and middle income countries in particular.

19 In a recent phase II trial the most advanced of those vaccine candidates, a PCV combined with  
20 pneumolysin toxoid and pneumococcal histidine triad protein D, failed to demonstrate any efficacy  
21 against carriage of serotypes not targeted by the PCV [8]. In particular for candidates in the  
22 pneumococcal vaccine pipeline that do not include a PCV component this raises a strategic question:  
23 “can a pneumococcal vaccine that only provides direct protection offset the lack of indirect  
24 protection with the benefit of additional direct protection against serotypes untargeted by current  
25 PCVs?”

26 In the following we assess the scope of pneumococcal vaccines that target the whole species and act  
27 to reduce disease risk but do not affect transmission.

28

29 **Methods**

30 *Data*

31 Currently two PCV formulations are available, a 13-valent PCV (PCV13) and a 10-valent PCV (PCV10)  
32 that targets a subset of PCV13's serotypes. We selected a convenience sample of four sites with  
33 robust surveillance for invasive pneumococcal disease (IPD) spanning at least 3 years before PCV  
34 introduction to at least 3 years after introduction. We selected Kilifi, Kenya [9] to represent a low-  
35 income PCV10 setting, the Gambia as a low income PCV13 setting [10], the Netherlands as a high  
36 income PCV10 setting [11] and England and Wales (E&W) as a high income PCV13 setting [12]. For  
37 each setting age-stratified incidence risk ratios ( $IRR_{PCV}$ ) for all serotype IPD incidence during PCV10 or  
38 PCV13 use in comparison with pre PCV were extracted. In the Gambia, the Netherlands and E&W the  
39 seven valent PCV (PCV7) had been in use before the current formulation. For both the Gambia and  
40 E&W the IRRs of PCV13 use in comparison with no vaccination were reported. For the Netherlands  
41 we multiplied reported IRRs to obtain the IRR of 3 years post PCV10 to early post PCV10 to pre  
42 PCV10 to pre PCV7. For Kilifi, Kenya we calculated the IRR based on reported 2008-2010 IPD  
43 incidence before PCVs and 2011-2015 incidence during PCV use.

44 *Analyses*

45 Clearly, a vaccine against all pneumococcal serotypes that does not limit transmission will need high  
46 clinical efficacy and a reasonable duration of vaccine protection to be competitive. We compared  
47 the impact of PCVs to the potential impact of a hypothetical pneumococcal vaccine candidate  
48 (HPVC) that acts to reduce the risk for IPD caused by any serotype by 90% for 5 years after  
49 vaccination and to lose its protective effect immediately thereafter. Based on typical DTP3 vaccine

50 coverage in low and high income countries [13] we assumed that such vaccine can be administered  
51 to immunise 75% and 95% of young infants in low and high income settings respectively. The  
52 predicted impact of HPVC was calculated as  $IRR_{HPVC} = 1 - (\text{vaccine efficacy} * \text{vaccine coverage})$  for all  
53 age bands including children up to 5 years old. The predicted impact of combined use of PCV and  
54 HPVC was calculated as  $IRR_{PCVHPVC} = IRR_{PCV} * IRR_{HPVC}$ .

55

## 56 Results

57 Low and high income countries differ substantially in which age groups contribute most to the  
58 overall burden of pneumococcal disease, in parts a result of differences in their demographic profile  
59 and life expectancy. Before the introduction of PCV in Kenya and the Gambia over 60% of IPD cases  
60 were reported among children younger than 5 years old. In contrast, IPD in children of that age in  
61 E&W and the Netherlands only accounted for less than 15% of all IPD (Figure 1 and Table 1).  
62 Consequently, among all IPD cases averted through PCVs use less than 25% and more than 75% have  
63 been averted among <5 year old children from the two high and the two low income countries  
64 respectively.

65 We estimate that in Kenya and the Gambia the HPVC could prevent 44% and 47% of all IPD while in  
66 E&W and the Netherlands it could only prevent 10% and 6%. In comparison, PCV was reported to  
67 prevent only slightly more IPD cases than that in the two low income settings, however, substantially  
68 more in the two high income settings (Figure 1). If assessed against the impact of routine PCV use  
69 against all IPD we find that use of a combined PCV and HPVC vaccine would add little impact in the  
70 two high income settings while it may offer substantial additional protection in the two low income  
71 countries.

72 When focussing on the impact in young children HPVC compares more favourably. In all four settings  
73 we predict that HPVC would be superior, if compared to the observed impact of PCV on IPD in young

74 children (Figure 2). We predict that HPVC could prevent 67.5% and 85.5% of childhood IPD in the low  
75 and high-income settings respectively. If given in combination with PCV, this impact could be  
76 increased to about 85% and 95% in the low and high-income settings respectively.

77

## 78 Discussion

79 National PCV infancy programmes have substantially reduced the pneumococcal disease burden. In  
80 particular in high income settings, much of that reduction can be attributed to indirect protection by  
81 limiting VT transmission. While vaccine candidates that do not prevent pneumococcal carriage will  
82 not induce such indirect protection, they may protect against disease from all pneumococci and will  
83 not cause serotype replacement. We show here that such candidate vaccine, if found highly  
84 protective against disease and given early in infancy can have similar or even superior impact among  
85 young children compared with PCVs. However, in high income settings the majority of the  
86 population impact of PCVs stems from the prevention of adult and elderly disease. Hence, HPVC use  
87 in such settings is likely to only achieve a small fraction of PCV's population impact.

88 Vaccines that target all pneumococci at once are designed with the ultimate goal to prevent the  
89 majority if not all pneumococcal disease. Pneumococcal vaccines that do not limit transmission will  
90 not achieve such goal. In fact, we show that even at high coverage and at high clinical efficacy they  
91 are likely to offer comparable population impact only in those settings where much of the  
92 pneumococcal disease burden is concentrated in young children. However, these settings are  
93 typically low income settings which also would benefit most from a major advantage of HPVC: they  
94 may be manufactured at a fraction of the costs of PCVs. In the near future many low income  
95 countries will need to take over the full costs of their pneumococcal vaccine programmes which are  
96 currently mainly paid for by Gavi, the Vaccine Alliance [14]. To continue PCV use some would need  
97 to more than double their current vaccine budget. An option to reduce pneumococcal vaccine costs

98 while sustaining similar impact could be the decisive factor for programme sustainability in these  
99 settings [15].

100 Unless supplemented by additional vaccination programmes, settings with a high disease burden in  
101 older individuals, like most high income countries, likely favour the indirect effects of the infant PCV  
102 programme over the added protection of HPVC in young children. In those settings a combined PCV  
103 and HPVC approach may offer an alternative use for HPVC. HPVCs can further reduce the residual  
104 childhood burden of pneumococcal disease and hence counter-act serotype replacement following  
105 PCV use. However, we estimate that combined PCV and HPVC use in the two high income settings  
106 may only prevent an additional 1-3% of all pneumococcal IPD and as a result would only achieve a  
107 similar cost-effectiveness profile to PCVs if HPVC can be used to immunise children at less than 5% of  
108 PCV costs.

109 Conducting a phase III trial with targeted clinical efficacy of about 90% for a vaccine that was found  
110 not to protect against pneumococcal carriage may need a leap of faith. In consolation though,  
111 aiming to detect only high efficacy comes with the advantage that it reduces the required sample  
112 size and, if successful, may offer a key tool for prevention of pneumococcal disease in low income  
113 settings. A further caveat is that the vaccine candidate will need to demonstrate that it protects not  
114 only against the most severe disease but also against non-bacteraemic pneumonia and otitis media  
115 which substantially contribute to the pneumococcal disease burden.

116 In conclusion, the success of PCVs has set a high benchmark for future pneumococcal vaccines.  
117 However, a vaccine against all pneumococci with high clinical efficacy and a moderate duration of  
118 protection given to young infants could help sustain or even further reduce the pneumococcal  
119 childhood disease burden in low income countries and at more sustainable costs, even if it fails to  
120 induce indirect protection.

121

122 Declaration of interest

123 Dr. Flasche has nothing to disclose.

124

125 Literature

126 [1] International Vaccine Access Center - Johns Hopkins Bloomberg School of Public Health.  
127 Global PCV introduction status n.d.

128 [2] O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease  
129 caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates.  
130 Lancet 2009;374:893–902.

131 [3] Pneumococcal vaccines. WHO position paper. *Relev Epidemiol Hebd* 1999;74:177–83.

132 [4] Klugman KP. Herd protection induced by pneumococcal conjugate vaccine. *Lancet Glob Heal*  
133 2014;2:e365–6.

134 [5] Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-specific  
135 changes in invasive pneumococcal disease after pneumococcal conjugate vaccine  
136 introduction: a pooled analysis of multiple surveillance sites. *PLoS Med* 2013;10:e1001517.

137 [6] Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal  
138 vaccination. *Lancet* 2011;6736:1–12.

139 [7] Alderson MR. Status of vaccine research and development of pediatric vaccines for  
140 *Streptococcus pneumoniae*. *Vaccine* 2016;34:2959–61.

141 [8] Odotola A, Ota MOC, Antonio M, Ogundare EO, Saidu Y, Foster-Nyarko E, et al. Efficacy of a  
142 novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of  
143 *Streptococcus pneumoniae* in infants: A phase 2, randomized, controlled, observer-blind  
144 study. *Vaccine* 2017;35:2531–42.

145 [9] Flasche S, Ojal J, Le Polain de Waroux O, Otiende M, O'Brien KL, Kiti M, et al. Assessing the  
146 efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a  
147 modelling study based on data from PCV10 introduction in Kilifi, Kenya. *BMC Med*  
148 2017;15:113.

149 [10] Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D, et al. Effect of the  
150 introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in  
151 The Gambia: a population-based surveillance study. *Lancet Infect Dis* 2016;3099:1–9.

152 [11] Knol MJ, Wagenvoort GHJ, Sanders EAM, Elberse K, Vlamincx BJ, de Melker HE, et al.  
153 Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal  
154 Conjugate Vaccine, the Netherlands. *Emerg Infect Dis* 2015;21:2040–4.

155 [12] Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of the 13-valent  
156 pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4  
157 years after its introduction: an observational cohort study. *Lancet Infect Dis* 2015;3099:1–9.

158 [13] World Health Organization. Monitoring and Surveillance - Vaccine Coverage Estimates n.d.

159 [14] Gavi The Vaccine Alliance. The transition process 2017.

160 [15] Flasche S, Van Hoek AJ, Goldblatt D, Edmunds WJ, O'Brien KL, Scott JAG, et al. The Potential

161 for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd  
162 Immunity in High-Income Countries. PLOS Med 2015;12:e1001839.

163

164



165 Figure 1: Cumulative age distribution of the proportion of IPD cases and IPD cases averted by either  
 166 PCV, a hypothetical vaccine (HPVC) or their combined use. The impact of PCVs refers to the  
 167 observed impact of PCV 13, 10, 10 and 13 in Gambia, Kenya, Netherlands and the UK in  
 168 comparison to no vaccination. The hypothetical vaccine is assumed to be delivered to 75%  
 169 of young infants and offer no indirect protection but 90% protection against all IPD for 5  
 170 years.

171 Figure 2: The proportion of IPD cases averted in children by either PCV a hypothetical vaccine (HPVC)  
 172 or their combined use.

173 Table 1: Overview of observed PCV impact across age groups in two low and two high income  
 174 countries with good IPD surveillance (sites). The incidence rate ratios (RR) in all instances  
 175 refer to ecological analyses of the population impact of the current PCV infant  
 176 immunisation programme in comparison to no vaccination.

Setting	Product in use	Age group	Cases before PCV	PCV RR	reference
Gambia	PCV13	2-11m	81	0.45	[10]
		12-23m	71	0.45	
		2-4y	9	0.44	
		5-14y	37	0.84	
		15+y	40	0.41	
Kenya	PCV10	<1y	27	0.40	[9]
		1-5y	61	0.32	
		6-14y	17	0.45	
		15-20y	1	0.60	
		21-49y	11	0.99	
		50y+	11	0.49	
Netherlands	PCV10	<2y	75	0.15	[11]
		2-4y	25	0.35	
		5-17y	22	0.74	
		18-49y	197	0.77	
		50-64y	273	0.88	
		65y+	717	0.75	
E&W	PCV13	<2y	710	0.23	[12]
		2-4y	319	0.26	
		5-14y	319	0.23	
		15-44y	1839	0.31	
		45-64y	2390	0.44	
		65y+	3045	0.6	